CWM LLC increased its position in Celgene Corporation (NASDAQ:CELG) by 9.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,467 shares of the biopharmaceutical company’s stock after buying an additional 3,773 shares during the period. CWM LLC’s holdings in Celgene Corporation were worth $5,775,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Ancora Advisors LLC raised its position in Celgene Corporation by 53.7% in the fourth quarter. Ancora Advisors LLC now owns 4,631 shares of the biopharmaceutical company’s stock valued at $536,000 after buying an additional 1,618 shares in the last quarter. Alkeon Capital Management LLC raised its position in Celgene Corporation by 3.1% in the fourth quarter. Alkeon Capital Management LLC now owns 1,818,555 shares of the biopharmaceutical company’s stock valued at $210,498,000 after buying an additional 55,460 shares in the last quarter. Soros Fund Management LLC acquired a new position in Celgene Corporation during the fourth quarter valued at about $405,000. Orbimed Advisors LLC raised its position in Celgene Corporation by 5.4% in the fourth quarter. Orbimed Advisors LLC now owns 3,106,777 shares of the biopharmaceutical company’s stock valued at $359,609,000 after buying an additional 158,200 shares in the last quarter. Finally, Hampstead Capital LLP acquired a new position in Celgene Corporation during the fourth quarter valued at about $4,630,000. 78.41% of the stock is owned by hedge funds and other institutional investors.
Shares of Celgene Corporation (NASDAQ CELG) opened at 135.27 on Wednesday. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $139.00. The company’s 50 day moving average is $133.32 and its 200 day moving average is $123.59. The company has a market cap of $105.83 billion, a P/E ratio of 41.89 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The company’s revenue was up 18.7% compared to the same quarter last year. During the same period last year, the firm posted $1.44 earnings per share. On average, equities research analysts predict that Celgene Corporation will post $7.32 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://stocknewstimes.com/2017/08/09/celgene-corporation-celg-shares-bought-by-cwm-llc-updated-updated.html.
Several research firms recently commented on CELG. Mizuho set a $134.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research note on Wednesday, July 26th. Cantor Fitzgerald set a $160.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, July 27th. Robert W. Baird reiterated an “outperform” rating and issued a $162.00 price objective on shares of Celgene Corporation in a research note on Friday, July 21st. Jefferies Group LLC reiterated a “buy” rating and issued a $160.00 price objective on shares of Celgene Corporation in a research note on Monday, July 31st. Finally, Cann reiterated a “buy” rating and issued a $175.00 price objective on shares of Celgene Corporation in a research note on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, six have given a hold rating and twenty-three have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $147.06.
In other Celgene Corporation news, insider Rupert Vessey sold 4,785 shares of the stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total transaction of $575,061.30. Following the transaction, the insider now directly owns 4,004 shares of the company’s stock, valued at $481,200.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Michael D. Casey sold 9,250 shares of the firm’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $125.59, for a total transaction of $1,161,707.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 235,255 shares of company stock worth $31,377,042. Insiders own 0.95% of the company’s stock.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
